Analysts expect Icon Plc (NASDAQ:ICLR) to post earnings of $1.30 per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Icon Plc’s earnings, with the highest EPS estimate coming in at $1.36 and the lowest estimate coming in at $1.26. Icon Plc reported earnings per share of $1.14 in the same quarter last year, which indicates a positive year-over-year growth rate of 14%. The business is expected to report its next earnings report before the market opens on Thursday, July 27th.

According to Zacks, analysts expect that Icon Plc will report full-year earnings of $5.17 per share for the current fiscal year, with EPS estimates ranging from $5.13 to $5.23. For the next fiscal year, analysts expect that the business will report earnings of $5.71 per share, with EPS estimates ranging from $5.41 to $5.91. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Icon Plc.

Icon Plc (NASDAQ:ICLR) last announced its earnings results on Thursday, April 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.02. Icon Plc had a return on equity of 28.89% and a net margin of 16.15%. The firm had revenue of $432 million during the quarter, compared to analyst estimates of $432.21 million. During the same period last year, the firm posted $1.12 EPS. The business’s revenue was up 7.9% compared to the same quarter last year.

ICLR has been the subject of several research analyst reports. Mizuho initiated coverage on Icon Plc in a research report on Thursday, March 23rd. They set a “neutral” rating and a $66.00 target price for the company. Jefferies Group LLC upgraded Icon Plc from a “hold” rating to a “buy” rating and raised their price target for the company from $86.00 to $117.00 in a report on Thursday, June 29th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $102.00 price objective (up from $91.00) on shares of Icon Plc in a research note on Tuesday, June 6th. Zacks Investment Research lowered Icon Plc from a “hold” rating to a “sell” rating in a research note on Wednesday, April 26th. Finally, Robert W. Baird decreased their price target on Icon Plc from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, June 9th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $96.00.

Shares of Icon Plc (NASDAQ:ICLR) opened at 98.77 on Wednesday. The company has a 50-day moving average price of $96.80 and a 200 day moving average price of $86.27. Icon Plc has a one year low of $70.54 and a one year high of $100.86. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of 20.50 and a beta of 0.59.

Several institutional investors have recently modified their holdings of the stock. Farmers & Merchants Investments Inc. raised its position in shares of Icon Plc by 11.5% in the first quarter. Farmers & Merchants Investments Inc. now owns 51,236 shares of the medical research company’s stock valued at $4,085,000 after buying an additional 5,269 shares during the period. UBS Asset Management Americas Inc. raised its position in Icon Plc by 43.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 234,818 shares of the medical research company’s stock worth $17,659,000 after buying an additional 70,654 shares during the last quarter. Legato Capital Management LLC raised its position in Icon Plc by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares during the last quarter. World Asset Management Inc raised its position in Icon Plc by 1.8% in the first quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock worth $275,000 after buying an additional 60 shares during the last quarter. Finally, Colony Group LLC raised its position in Icon Plc by 3.4% in the first quarter. Colony Group LLC now owns 23,400 shares of the medical research company’s stock worth $1,865,000 after buying an additional 780 shares during the last quarter. 92.64% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Icon Plc (ICLR) Will Announce Earnings of $1.30 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/19/brokerages-anticipate-icon-plc-iclr-will-announce-earnings-of-1-30-per-share.html.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon Plc (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.